Prestige Consumer Healthcare (NYSE:PBH) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Prestige Consumer Healthcare (NYSE:PBH) announced its quarterly earnings data on Thursday. The company reported $1.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.18 by $0.04, Zacks reports. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Prestige Consumer Healthcare updated its FY 2025 guidance to 4.500-4.500 EPS.

Prestige Consumer Healthcare Stock Down 0.4 %

NYSE:PBH opened at $86.96 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.10. Prestige Consumer Healthcare has a one year low of $60.00 and a one year high of $88.36. The firm’s 50 day simple moving average is $79.19 and its 200 day simple moving average is $75.34. The company has a market cap of $4.30 billion, a PE ratio of 20.37, a P/E/G ratio of 2.43 and a beta of 0.50.

Insider Activity

In other Prestige Consumer Healthcare news, EVP Adel Mekhail sold 9,063 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the transaction, the executive vice president now owns 18,365 shares in the company, valued at approximately $1,505,930. This trade represents a 33.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Ronald M. Lombardi sold 10,875 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the transaction, the chief executive officer now owns 320,952 shares in the company, valued at $26,510,635.20. This trade represents a 3.28 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 38,810 shares of company stock valued at $3,187,300. Insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on PBH shares. Canaccord Genuity Group lifted their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a research note on Friday. Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a research report on Monday, December 9th. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. DA Davidson upped their price objective on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research report on Friday. Finally, StockNews.com upgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Friday, January 24th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of “Moderate Buy” and an average price target of $92.50.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.